Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesEndocrinologyNeighborhood Health Plan Sephience Coverage Update…
    Ask Trek AI about this page
    CurrentNeighborhood Health Plan of Rhode IslandPolicy N/A

    Sephience (sepiapterin) — coverage criteria for sepiapterin‑responsive PKU

    Customize your policy alerts

    Sign up for all Neighborhood Health Plan of Rhode Island policy alerts

    Know when Neighborhood Health Plan of Rhode Island releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Covers use of Sephience (sepiapterin) for treatment of sepiapterin‑responsive phenylketonuria (HPA/PKU) in members aged ≥1 month when approval criteria are met; governs prior authorization, coverage duration, and clinical criteria for Neighborhood Health Plan of Rhode Island members.

    Policy Summary
    PayerNeighborhood Health Plan of Rhode Island
    PolicySephience (sepiapterin) — coverage criteria for sepiapterin‑responsive PKU
    Policy CodePolicy N/A
    Change TypeNo material change
    Effective Date02/2026
    Last ReviewNov 1, 2025
    Next Review Date11/2025
    Key ActionObtain prior authorization with documentation of diagnosis, baseline and historical phenylalanine measurements, weight, renal function, and prior sapropterin trial.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    1 monthminimum eligible age
    2 monthsinitial authorization

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    6 monthsrenewal authorization
    ≥360baseline Phe threshold
    ≥2 ≥600required past Phe history
    ≤60 mg/kgmax dose

    Coverage Criteria for Sephience (sepiapterin)

    Initial Therapy

    Covered when ALL of the following are met:

    Initial authorization criteria: A. The medication is prescribed by, or in consultation with, a physician who specializes in the treatment of metabolic disease and/or phenylketonuria (PKU).
    Initial authorization criteria: B. Member is one month of age or older.
    Initial authorization criteria: C. Member has been diagnosed with phenylketonuria and meets both of the following: 1) Past medical history of at least 2 blood phenylalanine measurements ≥600 μmol/L; AND 2) Baseline phenylalanine level ≥360 μmol/L prior to starting treatment with the requested medication.
    Initial authorization criteria: D. Member has not been diagnosed with hyperphenylalaninemia due to pathogenic variants in GCH1, PTS, QDPR, SPR, or PCBD1 (i.e., not primary BH4 deficiency).
    Initial authorization criteria: E. Documentation that the member does not have signs or laboratory findings of renal disease, including calculated GFR ≥60 mL/min/1.73 m2.GFR ≥60 mL/min/1.73 m2
    Initial authorization criteria: F. The requested medication will be used in conjunction with a phenylalanine‑restricted diet.
    Initial authorization criteria: G. Documentation that the requested medication will not be used in combination with sapropterin products (e.g., Javygtor, Kuvan) or pegvaliase (Palynziq).
    Initial authorization criteria: H. Documentation of the member's most recent weight.
    Initial authorization criteria: I. Medication is prescribed at the appropriate FDA‑approved weight‑based dose and does not exceed 60 mg/kg.Dose ≤60 mg/kg
    Initial authorization criteria: J. Member has had a documented inadequate treatment response or intolerance to a formulary sapropterin product (inadequate response defined as blood Phe ≥360 μmol/L despite consistent use with dietary Phe restriction).Baseline Phe ≥360 μmol/L; prior history ≥2 measures ≥600 μmol/L

    Initial approval duration: 2 months

    Renewal Therapy

    Covered when ALL of the following are met:

    Renewal criteria: A. Member continues to meet all initial criteria.
    Renewal criteria: B. Chart notes or medical records demonstrate achievement or maintenance of at least one of the following: 1) ≥30% decrease in phenylalanine levels from baseline; OR 2) Phenylalanine level <360 μmol/L; OR 3) Improvement in neuropsychiatric symptoms.Response: ≥30% Phe decrease or Phe <360 μmol/L

    Renewal authorization duration: 6 months

    All indications for Sephience (sepiapterin) other than the FDA‑approved indication—treatment of sepiapterin‑responsive hyperphenylalaninemia/phenylketonuria (HPA/PKU) in patients aged 1 month or older when used as an adjunct to a phenylalanine‑restricted diet—are considered experimental/investigational and not medically necessary. Requests for treatment of conditions outside this indication will be denied.

    Use of Sephience (sepiapterin) for any indication other than sepiapterin‑responsive HPA/PKU in patients aged 1 month and older, as specified in the FDA‑approved labeling, is not medically necessary and will not be covered.

    Clinical Thresholds, Dosing, and Lab Requirements

    Phenylalanine (Phe) levels
    Baseline phenylalanine (Phe)Baseline Phe ≥360 μmol/L prior to starting therapy
    Historical Phe measurementsPast medical history of at least 2 blood Phe measurements ≥600 μmol/L
    Renewal response criteriaRenewal requires either ≥30% decrease in Phe from baseline or Phe <360 μmol/L (or clinical improvement in neuropsychiatric symptoms)
    Estimated GFR
    Minimum renal functionCalculated GFR ≥60 mL/min/1.73 m2 required
    Documentation requirementDocumentation that member has no signs/symptoms of renal disease and GFR is ≥60 mL/min/1.73 m2

    Prior Authorization, Documentation, and Denial Conditions

    Prior Authorization

    Prior Authorization Required

    Prior authorization is required. Initial approvals may be granted for 2 months; renewals may be granted for 6 months when continuation criteria are met.

    • Initial approval duration: 2 months
    • Renewal approval duration: 6 months when renewal criteria are satisfied
    Step Therapy

    Step Therapy Requirement

    Member must have had a documented inadequate response or intolerance to a formulary sapropterin product prior to approval. Inadequate response is defined as blood phenylalanine (Phe) ≥360 μmol/L despite consistent use in combination with dietary Phe restriction.

    • Step therapy requirement: trial of formulary sapropterin with documented inadequate response or intolerance
    • Definition of inadequate response: Phe ≥360 μmol/L despite compliant use plus Phe-restricted diet

    Background

    Sephience (sepiapterin) is indicated, per FDA labeling, as an adjunct to a phenylalanine‑restricted diet for the treatment of sepiapterin‑responsive hyperphenylalaninemia/phenylketonuria (HPA/PKU) in adult and pediatric patients aged 1 month and older. Therapy should be used with dietary Phe restriction; use for other diagnoses is considered experimental/investigational and not medically necessary.

    Definitions and Diagnostic Exclusions

    Inadequate response to sapropterin
    Definition of inadequate response to sapropterinBlood phenylalanine ≥360 μmol/L despite consistent use of sapropterin in combination with dietary Phe restriction
    Context for step therapyDocumented inadequate response or intolerance to a formulary sapropterin product is required prior to approval
    Evidence requiredClinical records should show persistent Phe ≥360 μmol/L while on sapropterin plus Phe‑restricted diet
    Primary BH4 deficiency exclusion
    Exclusion of primary BH4 deficiencyMember must not have hyperphenylalaninemia due to pathogenic variants in GCH1, PTS, QDPR, SPR, or PCBD1
    Documentation neededMedical record must indicate absence of a diagnosis of primary BH4 deficiency (no pathogenic variants in listed genes)
    Policy Summary
    PayerNeighborhood Health Plan of Rhode Island
    PolicySephience (sepiapterin) — coverage criteria for sepiapterin‑responsive PKU
    Policy CodePolicy N/A
    Change TypeNo material change
    Effective Date02/2026
    Last ReviewNov 1, 2025
    Next Review Date11/2025
    Key ActionObtain prior authorization with documentation of diagnosis, baseline and historical phenylalanine measurements, weight, renal function, and prior sapropterin trial.
    SourceLink
    On This Page
    Coverage Criteria for Sephience (sepiapterin)Clinical Thresholds, Dosing, and Lab RequirementsPrior Authorization, Documentation, and Denial ConditionsBackgroundDefinitions and Diagnostic Exclusions
    Exclusion trigger
    GFR <60 mL/min/1.73 m2 is indicative of renal disease and does not meet authorization criteria
    Maximum dose
    Maximum weight‑based doseDose must not exceed 60 mg/kg
    FDA‑approved dosingMedication must be prescribed at the appropriate FDA‑approved dose based on the member's weight
    Documentation requirementProvider must document the member's most recent weight to confirm dosing
    Documentation Required

    Documentation Required at Submission

    Submit clinical notes or medical records documenting diagnosis and required laboratory values. At minimum include: prior Phe measurements (at least two historical measurements ≥600 μmol/L), a baseline Phe measurement ≥360 μmol/L prior to starting treatment, documentation of the member’s most recent weight, and documentation that the medication will be used with a Phe‑restricted diet.

    • Required documentation: ≥2 historical blood Phe measurements ≥600 μmol/L
    • Baseline Phe ≥360 μmol/L prior to treatment start
    • Member’s most recent weight
    • Plan to use medication with a Phe‑restricted diet
    Documentation Required

    Renewal Documentation

    For renewal requests, provide chart notes or medical records demonstrating clinical benefit: either a ≥30% decrease in Phe from baseline, Phe <360 μmol/L, or improvement in neuropsychiatric symptoms.

    • Renewal documentation: ≥30% reduction in Phe from baseline OR Phe <360 μmol/L OR documented improvement in neuropsychiatric symptoms
    Denial Risk

    Indication Limitations

    Use for indications other than FDA‑approved sepiapterin‑responsive HPA/PKU (in patients ≥1 month of age) is considered experimental/investigational and not medically necessary.

    • Indication limited to sepiapterin‑responsive hyperphenylalaninemia (HPA)/PKU in patients ≥1 month old and used with a Phe‑restricted diet
    • All other indications: experimental/investigational — not medically necessary
    Denial Risk

    Concurrent Prohibited Therapies

    Concurrent use with sapropterin products (e.g., sapropterin, Javygtor, Kuvan) or pegvaliase (Palynziq) is prohibited and may result in denial.

    • Do not prescribe in combination with sapropterin products or Palynziq (pegvaliase-pqpz)
    • Concurrent therapy with these agents may trigger claim denial
    Denial Risk

    Insufficient Laboratory or Prescriber Documentation

    Failure to document required laboratory values (baseline and prior Phe measurements meeting thresholds) or specialist prescribing/consultation may lead to denial for insufficient documentation.

    • Insufficient lab documentation: missing baseline Phe ≥360 μmol/L or fewer than two historical Phe ≥600 μmol/L
    • Prescriber requirement: prescribed by or in consultation with a physician specializing in metabolic disease/PKU
    Impact on eligibilityA diagnosis of primary BH4 deficiency (pathogenic variants in these genes) excludes the member from coverage under these criteria